Hematology

December 10th 2024

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

November 29th 2024

Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.

November 26th 2024

The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.

November 26th 2024

In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.